



Hypothermic effects on gas exchange performance of membrane oxygenator and blood coagulation during cardiopulmonary bypass in pigs

Journal:	<i>Perfusion</i>
Manuscript ID	PRF-19-0133.R2
Manuscript Type:	Original Manuscript
Date Submitted by the Author:	n/a
Complete List of Authors:	Akeho, Kazuhiro; Shimane University Hospital, Department of Medical Engineering Nakata, Hayato; Shimane University Hospital, Department of Medical Engineering Suehiro, Shoichi; Shimane University Faculty of Medicine, Division of Thoracic and Cardiovascular Surgery, Department of Surgery Shimizu, Kouji; Shimane University Faculty of Medicine, Division of Thoracic and Cardiovascular Surgery, Department of Surgery Imai, Kensuke; Shimane University Faculty of Medicine, Division of Thoracic and Cardiovascular Surgery, Department of Surgery Yamaguchi, Akane; Shimane University Faculty of Medicine, Division of Thoracic and Cardiovascular Surgery, Department of Surgery Matsumoto, Ken-ichi; Shimane University, Department of Biosignaling and Radioisotope Experiment, Interdisciplinary Center for Science Research, Organization for Research Oda, Teiji; Shimane University Faculty of Medicine, Division of Thoracic and Cardiovascular Surgery, Department of Surgery
Keywords:	Biocompatibility, Blood coagulation, platelet activation, hypothermia, cardiopulmonary bypass, proteomics, deep hypothermic circulatory arrest, pediatric heart surgery
Abstract:	<p>Introduction: Whether hypothermic cardiopulmonary bypass (CPB) could attenuate both blood coagulation and platelet activation compared to normothermic CPB remains elusive.</p> <p>Methods: Biocompatibility of a polymer-coated CPB circuit was comparatively assessed by plasma proteomics between juvenile pigs undergoing hypothermic (23°C) CPB and those undergoing normothermic (37°C) CPB (n = 6, respectively). Plasma samples were taken 3 times: 5 min after initiation of CPB (T5, before cooling), just before declamping and rewarming (Tc) and just before termination of CPB (Trw, 120 min). Proteomic analysis was quantitatively performed by isobaric tags for relative and absolute quantification labeling. Thrombin-antithrombin complexes (TAT III) were measured by enzyme immunoassay, and vitamin K-dependent protein C (PROC), β-thromboglobulin (TG) and p-selectin were measured by enzyme-linked immunosorbent assay. Blood gas analyses evaluated oxygenator performance.</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<p>Results: Hypothermic CPB had a significantly higher PaO₂ at Tc and lower PaCO₂ at Trw than normothermic CPB. 224 proteins were identified with statistical criteria of both protein confidence (>95%) and false discovery rate (FDR<5%). Six of these proteins significantly decreased at Tc than at T5 in hypothermic CPB (p = 0.02-0.04), with three related to platelet degranulation. Protein C decreased at Trw compared with T5 in normothermic CPB (p = 0.04). TAT had a slightly larger increase with normothermic CPB at Trw than with hypothermic CPB. β-TG and P-selectin levels were significantly lower at Trw with hypothermic CPB than with normothermic CPB (p =0.04). Conclusion : Hypothermic CPB attenuated platelet degranulation/blood coagulation and maintained better oxygenator performance compared to normothermic CPB in juvenile pigs.</p>

SCHOLARONE™
Manuscripts

1
2
3 **Hypothermic effects on gas exchange performance of membrane oxygenator and blood coagulation during**
4 **cardiopulmonary bypass in pigs.**
5
6

7 **K Akeho ¹, H Nakata ¹S Suehiro², K Shimizu², K Imai², A Yamaguchi ², K Matsumoto ³, T Oda ².**
8
9

10
11
12 **Keywords**

13 **Biocompatibility, blood coagulation, platelet activation, hypothermia, cardiopulmonary bypass, proteomics**
14
15

16
17 **¹Department of Medical Engineering, Shimane University Hospital, Izumo, Japan**

18 **²Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Shimane University Faculty of**
19 **Medicine, Izumo, Japan**

20 **³Department of Biosignaling and Radioisotope Experiment, Interdisciplinary Center for Science Research,**
21 **Organization for Research, Shimane University, Izumo, Japan**
22
23
24
25
26

27 **Corresponding author:**

28 **Prof. Teiji Oda M.D., Ph.D.**

29 **Division of Thoracic and Cardiovascular Surgery**

30 **Department of Surgery**

31 **Shimane University Faculty of Medicine**

32 **89-1 Enya-cho**

33 **Izumo 693-8501**

34 **Japan.**

35 **Email: toda@med.shimane-u.ac.jp**
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

It remains uncertain whether hypothermia could reduce blood component activation by contact with the cardiopulmonary bypass (CPB) circuit. On the other hand, many studies have shown that hypothermia could reduce inflammation caused by ischemic/traumatic injuries¹. Evidence has been convincing that there is crosstalk between inflammation and blood coagulation^{2,3}. Hypothermia was also shown to decrease [complement](#), coagulation, [neutrophil](#) and platelet activities during/after surgery [with CPB](#) or therapeutic hypothermia⁴⁻¹⁰. [However, there have been several evidences that moderate hypothermic \(24°C, 25°C\) CPB could not impact on cytokine levels compared to mild \(32°C, 34°C\) one in pediatric cardiac surgery^{11,12}. Furthermore, the CPB-induced inflammation has been shown to be stronger in children compared with adults because of simply small body size relative to CPB circuit size¹¹.](#) The objective of this study was to ascertain whether [deep \(23°C\)](#) hypothermic CPB reduces blood component activation including blood coagulation compared with normothermic CPB [in juvenile pigs](#); with both procedures the circuits were fully polymer-coated. [The deep hypothermic CPB has been widely used in complex congenital surgeries such as Norwood procedure or aortic arch reconstruction in order to safely extend hypothermic circulatory arrest time.](#) We previously reported that a polymer-coated CPB circuit attenuated up-regulation of proteins in both proteases/protease inhibitors and platelet degranulation¹³. The aim of this study was to verify whether [deep](#) hypothermic CPB could reduce upregulation of blood proteins activated by contact with a polymer-coated CPB circuit [in juvenile pigs](#).

Materials and Methods

Animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals prepared by Shimane University Faculty of Medicine and the experimental protocol was approved by the Ethics Committee of the Ethics of Shimane University. The anesthetic and experimental procedures were performed as described previously¹³. In brief, 12 domestic [juvenile](#) pigs (body weight = 16 kg) were randomized into two groups: the normothermic (37°C) CPB group and hypothermic (23°C) CPB group (n = 6, respectively). After an overnight fast with free access to water, animals were premedicated by intramuscular injection of ketamine (20 mg/kg), xylazine (3 mg/kg) and 0.5 mg of atropine. Anesthesia was induced by bolus infusion of propofol (2 mg/kg), fentanyl (12.4 µg/kg) and rocuronium bromide (1 mg/kg). After tracheal intubation, animals were mechanically ventilated with 50% oxygen in air, and anesthesia was maintained by inhalation of 1.3% of isoflurane. During full CPB support, anesthetic maintenance was switched to continuous infusion of fentanyl (1 µg/kg/h~20 µg/kg/h), propofol (6–8 mg/kg/h) and rocuronium bromide (1.5 mg/kg/h). Throughout the experiment,

1
2
3
4
5
6 acetated Ringer's solution with 40 ml of 20% glucose solution was administered (6 ml/kg/h) in both
7 groups. Heart rate was monitored together with rectal temperature and arterial blood pressure obtained
8 from the right femoral artery by Power Lab (ML846, ADInstruments, Nagoya, Japan)¹³.
9

10 11 ***Surgical procedures and hypothermic/normothermic CPB*** 12

13
14 All animals underwent median sternotomy in the supine position under aseptic conditions¹³. After a bolus
15 infusion of heparin (4 mg/kg), a 14 Fr aortic cannula was inserted into the ascending aorta and an 18 Fr
16 angled single venous cannula was inserted into the superior vena cava. After initiation of CPB, an 18 Fr
17 straight venous single cannula was inserted into the right atrium and advanced into the inferior vena cava.
18 Pump flow was set about 1 l/min, which was equal to the cardiac output determined just before CPB
19 initiation by a conductance catheter and its system (Unique Medical, Tokyo, Japan). When necessary,
20 acetated Ringer's solution was added to maintain pump flow. In the hypothermic group animals, 5 min
21 after initiation of ECC and the first blood sampling (T5), hypothermia was introduced by rapid core
22 cooling to a rectal temperature of 22°C in 25 min with surface cooling. In contrast, animals in the
23 normothermic CPB group were kept under a normothermic condition of 37°C during 120 min of the CPB
24 procedure. Thirty min later, the ascending aorta was cross-clamped, and cardioplegic arrest of the heart
25 was achieved by delivering blood cardioplegic solution. The same dose of cardioplegic solution was
26 administered 30 min later. At 60 min of aortic cross clamp, the second blood sample (Tc) was taken, and
27 then the cross clamping was released after infusion of 20 mg xylocaine. After 30 min of assisted
28 circulation in the normothermic group or rapid rewarming up to 37°C in the hypothermic CPB group and
29 the third blood sampling (Trw), all animals were successfully weaned from the CPB and received all
30 blood that remained in the reservoir and the tubing.
31

32 The CPB circuit consisted of a hollow-fiber membrane oxygenator combined with a hard-shell reservoir
33 and a roller pump (Terumo Sarns 8000, Tokyo, Japan). In both groups, all areas of the CPB circuit in
34 contact with blood were coated with ternalpolymer (SEC-coating, HPO-06RHF-C, Senko Medical
35 Instrument Manufacturing Co., Ltd., Tokyo, Japan)¹³. The CPB priming fluid consisted of 440 ml of
36 acetated Ringer's solution (including 1500 U of heparin and 50 ml of 20% mannitol) in order to achieve
37 the minimum filling level (55 ml) of the reservoir.
38
39

40 41 ***Data collection and measurement*** 42

43 Pump flow, gas flow, percentage of oxygen, arterial pressure, heart rate and rectal temperature were
44 manually recorded every 5 min. Arterial blood gases were analyzed every 30 min by i-STAT (Abbott
45 Point Of Care, Princeton, NJ, USA), PaCO₂ was measured at 37°C (α -stat strategy), and gas flow was
46 adjusted to keep PaO₂ >100 mmHg. Hypoglycemia was treated by bolus infusion of 20% glucose
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 solution. Rectal temperature was controlled by a heat exchanger, cooling/warming blanket and room
7 temperature control. Blood samples were taken 5 min after initiation of CPB and just before cooling (T5),
8 just before declamping and rewarming (90 min after the initiation of CPB, Tc) and just before termination
9 of CPB (Trw, after rewarming). Blood samples were centrifuged at 1,400 x g for 5 min, and the plasma
10 layers were stored at -80°C.
11
12

13 14 ***Immunodepletion of abundant proteins***

15
16
17 The two most abundant plasma proteins, albumin and immunoglobulin G, were removed using an
18 immunodepletion column (Albumin & IgG Depletion SpinTrap, GE Healthcare, Buckinghamshire, UK)
19 in accordance with the manufacturer's instructions and as reported previously¹⁴.
20
21
22

23 24 ***iTRAQ labeling and strong cation exchange (SCX) chromatography***

25
26 Samples were prepared according to instructions published by SCIEX (Concord, Canada) and as
27 published previously¹⁴. Briefly, equal amounts of immunodepleted T5, Tc and Trw samples from each
28 animal were denatured and reduced and the cysteines were alkylated and digested with trypsin (SCIEX).
29 Each digest was labeled with a different iTRAQ tag using the iTRAQ reagent 4-plex kit (SCIEX). iTRAQ
30 label 114 was chosen for the T5 sample, and iTRAQ labels 115, 116 or 117 were randomly selected for
31 the Tc and Trw samples; the three samples from each animal were then combined. The combined samples
32 were then fractionated into six fractions by SCX chromatography according to the manufacturer's
33 instructions (SCIEX), and each fraction was desalted according to the manufacturer's manuals (Waters,
34 Milford, MA, USA).
35
36
37
38
39
40
41

42 43 ***NanoLC and MALDI-TOF/TOF MS/MS analysis***

44
45 One fraction from SCX chromatography was fractionated to 171 spots using a DiNa nanoLC system
46 (KYA Tech, Tokyo, Japan) and collected onto an Opti-TOF LC/MALDI 384 target plate (SCIEX)
47 according to the manufacturer's instructions and as reported previously¹⁴. Spotted peptide samples were
48 analyzed by a 5800 MALDI-TOF/TOF MS/MS Analyzer with TOF/TOF Series software (version 4.0,
49 SCIEX). MS/MS data were analyzed using ProteinPilot™ software (version 3.0) and the Paragon™
50 protein database (SCIEX) after adding a sus scrofa FASTA file downloaded from NCBI for database
51 searching. Quantitative changes in protein abundance at Tc or Trw were calculated using the iTRAQ
52 ratios Tc:T5 or Trw:T5, respectively.
53
54
55
56
57

58 59 ***ITRAQ data analysis***

1
2
3
4
5
6
7 Proteins identified were assessed to determine if they met the following two conditions: 1) a false
8 discovery rate (FDR) <5% (FDR was estimated by “decoy database searching” using ProteinPilot
9 Software); and 2) protein confidence >99% (“unused ProtScore” >2). Proteins meeting those criteria are
10 defined here as having “statistical significance”^{14,15}. The annotations of identified proteins were acquired
11 from the Uniprot database (<http://www.uniprot.org/>). For an unclassified protein whose protein name or
12 gene name for sus scrofa was not attainable by the ProteinPilot software, we searched for its orthologous
13 protein by a database for the orthologous group, EggNOG4.5 (<http://eggnogdb.embl.de/#/app/home>)¹⁶
14 and Inparanoid8 (<http://inparanoid.sbc.su.se/cgi-bin/index.cgi>)¹⁷.

21 *Enzyme-linked immunosorbent assay (ELISA)*

22
23 Levels of vitamin K-dependent protein C (PROC), β -thromboglobulin (TG) and P-selectin were measured
24 using each sandwich ELISA kit according to its respective manual (Pig PROC kit, LifeSpan BioSciences,
25 Inc., Seattle, WA, USA; pig β -TG ELISA kit, MyBioSource, San Diego, CA, USA; Pig soluble P-selectin
26 ELISA kit, CUSABIO, Houston, TX, USA). The levels of thrombin-antithrombin complexes (TAT III)
27 were measured by enzyme immunoassay.
28
29
30
31

32 *Statistical analysis*

33
34
35 iTRAQ ratios (Tc/T5 ratio, Trw/T5 ratio) were expressed as mean \pm standard deviation (SD) and
36 statistically analyzed regarding differences within groups by using 1-sample t-test of the average protein
37 ratio against 1 to evaluate the validity of protein expression changes^{14,15}. Continuous variables were
38 expressed as mean \pm standard deviation (SD) or expressed as median and quartiles [Q1, Q3] or box-and -
39 whisker plot. Statistical significance was assessed between two groups by the Mann-Whitney U test, and
40 comparisons among three sampling/measurement points in each group were analyzed by the Wilcoxon
41 signed-ranked test with Bonferroni corrections (SPSS Statistics 24.0 for Windows, IBM Corp. Chicago,
42 IL, USA). $P < 0.05$ was defined as statistically significant.
43
44
45
46
47
48

49 **Results**

50
51
52 There were no significant differences between the two groups in pump parameters and results of blood
53 gas analyses at T5 before cooling (Table 1), **although there were relatively large individual**
54 **differences in PO₂, PCO₂, and glucose values at T5.**

55 . After cooling, PaO₂ increased more markedly at Tc than at T5 in the hypothermic group ($P = 0.188$), while
56 it decreased in the normothermic group; thereby the difference in PaO₂ between groups reached statistical
57
58
59
60

1
2
3
4
5
6 significance ($P = 0.019$) despite a significant difference in FiO_2 between groups ($P = 0.045$). Therefore, the
7 P/F ratio, i.e., the ratio of PaO_2 divided by FiO_2 , an index of pulmonary oxygenation¹⁸, increased at Tc in
8 the hypothermic group, but decreased in the normothermic group at Tc ($P = 0.094$); the difference at Tc
9 between groups was statistically significant ($P = 0.019$). Level of $PaCO_2$ was significantly higher at Trw in
10 the normothermic group than in the hypothermic group ($P = 0.01$), despite the significantly larger gas flow
11 in the normothermic group than in the hypothermic group ($P = 0.048$). In animals having hypothermic CPB,
12 the hemoglobin level had a greater decrease at Tc than at T5 ($P = 0.375$) and thereafter increased at Trw,
13 although the difference between groups did not reach statistical significance ($P = 0.062$). Infusion volume
14 during CPB was 785 [450, 880] ml in animals undergoing hypothermic CPB and 275 [60, 355] ml in those
15 undergoing normothermic CPB, for a statistically significant difference ($P = 0.0017$).

16 All proteins identified with high confidence are shown in a scatter plot graph in which each protein is
17 expressed by the log-transformed iTRAQ ratio and p-values (Figure 1). At the midpoint of CPB, the trend
18 of protein downregulation was prominent in the hypothermic group although there was a wide range of
19 variation of protein fold changes in the normothermic group. Several proteins related to
20 coagulation/fibrinolysis were upregulated in the normothermic group, although without statistical
21 significance (Figure 1A, B). Eight proteins decreased with statistical significance during both hypothermic
22 and normothermic CPB (Table 2). Among these, proteins belonging to platelet degranulation, APOH,
23 APOA1, SERPINA3-1, were slightly but significantly downregulated during cooling (Tc). Furthermore,
24 the level of vitamin K-dependent protein (PROC), a physiologic anticoagulant, was significantly
25 downregulated in animals with normothermic CPB at Trw ($P = 0.001$) although the level of PROC increased
26 in animals undergoing hypothermic CPB ($P = 0.069$).

27 ELISA analysis demonstrated that levels of β -TG and P-selectin were significantly higher in
28 normothermic animals than in hypothermic animals at Trw ($P = 0.041$, Figure 2A, B). TAT III was more
29 upregulated at Trw in the normothermic group than in the hypothermic group, although the difference did
30 not reach statistical significance ($P = 0.258$, Figure 3A). There was no difference in administered heparin
31 doses between groups (61 [48, 68] mg in normothermic animals, 56 [48, 64] mg in hypothermic animals).
32 In ELISA analysis, protein C was upregulated at Tc (during cooling), with a small difference between
33 hypothermic and normothermic animals ($P = 0.180$, Figure 3B).

34 Discussion

35 A wide range of measures have been studied so far to improve biocompatibility in CPB¹⁹. However, to
36 our knowledge, this is the first study to assess the effects of hypothermia on the biocompatibility of CPB
37 circuits by comparing both oxygenator performance and plasma proteomes between hypothermic CPB and
38 normothermic CPB in which all experiments in both groups were performed under the same conditions

1
2
3
4
5
6 except for temperature management. Hypothermic CPB improved oxygenation by oxygenators during
7 blood cooling at Tc. This improvement was simply thought to reflect the physiologic changes whereby
8 lowering the temperature increases blood solubility of oxygen by 1.2%/°C and hemoglobin affinity of
9 oxygen by 7.4%/°C (at SO₂<80%)^{20,21}, resulting in increased oxygen transfer by oxygenators²². However,
11 reduced oxygen consumption by hypothermia leads to increased venous oxygen tension. This consequence
12 necessarily decreases oxygen transfer in oxygenators by Fick's law because oxygen diffusion decreases
13 due to the decreased oxygen partial pressure gradient between gas flowing inside capillary membranes and
14 venous blood flowing outside membranes in the oxygenator²³. However, hemodilution by the pump priming
15 solution can reduce oxygen delivery (oxygen in ml/100ml of blood) and thereby increase the oxygen
16 extraction rate resulting in a lower venous PO₂. Taken together, hypothermic CPB could augment the
17 oxygen transfer ability of oxygenators, but the actual oxygen transfer varies with body temperature, oxygen
18 consumption, pump flow and hemoglobin levels.

19
20 After two hours of CPB, elimination of CO₂ gas by oxygenators decreased in normothermic CPB
21 compared to hypothermic CPB. This phenomenon could reflect some sort of deterioration of membrane
22 oxygenator performance in normothermic CPB. However, further study is needed to elucidate the true
23 mechanism.

24
25 Hypothermia is generally thought to impair or suppress blood coagulation which was evaluated by
26 bleeding time, APTT, PT, thrombelastography, and enzyme activity^{4,5,7,9,24}. Our study also demonstrated
27 that hypothermic CPB suppressed upregulation of proteins belonging to coagulation/fibrinolysis and TAT

28
29
30
31
32
33
34
35 III. Proteomic and ELISA analyses demonstrated that levels of protein C were slightly increased during
36 cooling (at Tc) in hypothermic CPB, while proteomic analysis showed a significant decreased level of
37 protein C at Trw in normothermic CPB. A recent study showed that protein C, a physiologic anticoagulant,
38 was upregulated in animals having mild hypothermia (33°C) after cardiac arrest⁹.

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Whether platelet degranulation could be suppressed or activated by hypothermia remains controversial.
In this study, levels of two platelet activation markers, β-TG and P-selection, were lower in the hypothermic
CPB group than in the normothermic CPB group at Trw, indicating that hypothermia could attenuate
platelet degranulation induced by exposure to the CPB circuit. This was consistent with previous studies^{7,9}.
However, Straub et al. reported that hypothermia or lowering the temperature activated platelet function
and thereby upregulated p-selection expression by increased levels of ADP^{25,26}. On the other hand,
Swoboda et al. reported that hypothermia inhibited expressions of CD11b and CD162 (p-selectin) on
monocytes in an in vitro circulation model, which may lead to the inhibition of monocyte-endothelial and
monocyte-platelet interaction²⁷.

In hypothermic CPB, the hemoglobin level decreased at Tc and then increased at Trw; however, such
changes did not occur in normothermic CPB. This could result from the significantly larger infusion volume
in hypothermic CPB than in normothermic CPB (785 [450, 880]ml vs. 275 [60, 355]ml). Unlike surface

1
2
3
4
5
6 cooling that increases venous return, perfusion hypothermia, i.e., core cooling by CPB, decreases venous
7 return because of an increased vascular capacity²⁸. Therefore, in order to maintain the pump reservoir level,
8 a larger volume of infusion is mandatory in hypothermic CPB compared with normothermic CPB. **This**
9 **large infusion volume might affect protein abundance in hypothermic CPB group, but the equal**
10 **amounts proteins (100 µg) of immunodepleted plasma samples were prepared to analyze and**
11 **thereby such dilution cannot affect iTRAQ ratios in both groups.**

12
13
14 The limitations of the present study are: 1) inadequate investigation into p-selection degranulation from
15 platelets and 2) no macro- and microscopic investigations of membrane oxygenators after experiments in
16 order to search for any thrombus outside hollow fibers or the water content stored in hollow fibers due to
17 condensation. Therefore, further studies are needed to elucidate these issues in order better to understand
18 hypothermic effects on CPB biocompatibility. **In order to obtain more wide range of findings,**
19 **additional studies using adult animals at different temperatures, i.e., moderate hypothermia (25-**
20 **30°C) or mild hypothermia (31-34°C) are required.**

21
22
23
24
25
26
27 In conclusion, the present study of juvenile pig CPB experiments revealed that hypothermic (23°C)

28
29 CPB attenuated both blood coagulation and platelet degranulation activated by contact with the CPB
30 circuit compared with those in normothermic CPB. Furthermore, hypothermic CPB was accompanied by
31 a higher performance of the oxygenator compared with normothermic CPB.
32
33
34

35 **Declaration of Conflicts of Interest**

36
37 The authors declare that there are no conflicts of interest.
38
39
40

41 **Funding**

42
43 This study was not funded by any public or private agency.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. *Crit Care Med* 2009;37: S186-S202.
2. Rezaie AR. Regulation of the protein C anticoagulant and antiinflammatory pathways. *Curr Med Chem* 2010; 17: 2059-2069.
3. Esmon CT. Reprint of Crosstalk between inflammation and coagulation. *Maturitas* 2008; 61: 122–131.
4. Valeri CR, Cassidy G, Khuri S, et al. Hypothermia-induced reversible platelet dysfunction. *Ann Surg* 1987; 205:175-181.
5. Valeri CR, MacGregor H, Cassidy G, et al. Effects of temperature on bleeding time and clotting time in normal male and female volunteers. *Crit Care Med* 1995; 23: 698-704.
6. Watts DD, Trask A, Soeken K, et al. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. *J Trauma Acute Care Surg* 1998; 44: 846-854.
7. Wolberg AS, Meng ZH, Monroe III DM, et al. A systemic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. *J Trauma* 2004; 56: 1221-1228.
8. Chun-Lin H, Jie W, Xiao-Xing L, et al. Effects of therapeutic hypothermia on coagulopathy and microcirculation after cardiopulmonary resuscitation in rabbits. *Am J Emerg Med* 2011; 29: 1103-1110.
9. Gong P, Zhang MY, Zhao H, et al. Effect of mild hypothermia on the coagulation-fibrinolysis system and physiological anticoagulants after cardiopulmonary resuscitation in a porcine model. *PLOS one* 2013; 8: e67476.
10. [Chello M, Mastroroberto P, Romano R, et al. Complement and neutrophil activation during cardiopulmonary bypass. A randomized comparison of hypothermic and normothermic circulation. *Eur J Cardiothorac Surg* 1997; 11: 162-168.](#)
11. [Eggum R, Ueland T, Mollnes TE, et al. Effect of perfusion temperature on the inflammatory response during pediatric cardiac surgery. *Ann Thorac Surg* 2008; 85: 611-7.](#)
12. [Stocker CF, Shekerdemian LS, Horton SB, et al. The influence of bypass temperature on the systemic inflammatory response and organ injury after pediatric open surgery: a randomized trial. *J Thorac Cardiovasc Surg* 2011; 142: 174-80](#)
13. Suehiro S, Shimizu K, Imai K, et al. Polymer-coated cardiopulmonary bypass circuit attenuates upregulation of both proteases/protease inhibitors and platelet degranulation in pigs. *Perfusion* 2017; 32: 645-655.
14. Oda T, Yamaguchi A, Yokoyama M, et al. Plasma proteomic changes during hypothermic and

- normothermic cardiopulmonary bypass in aortic surgeries. *Int J Mol Med* 2014; 34:947-956.
15. Oda T, Yamaguchi A, Shimizu K, et al. Does the rewarmed heart restore the myocardial proteome to that of the precooled state? *Circ J* 2015; 79: 2648-2658.
16. Huerta-Cepas J, Szklarczyk D, Forslund K, et al. eggNOG 4.5: a hierarchical orthology framework with improved functional annotations for eukaryotic, prokaryotic and viral sequences. *Nucleic Acids Res* 2016; 44: D286-D293.
17. Sonnhammer ELL, Ostlund G. InParanoid 8: orthology analysis between 273 proteomes, mostly eukaryotic. *Nucleic Acids Res* 2015; 43: D234-D239.
18. Covelli HD, Nesson VJ, Tuttle WK 3rd, Oxygen derived variables in acute respiratory failure. *Crit Care Med* 1983; 11: 646-649.
19. Landis RC, Brown JR, Fitzgerald D, et al. Attenuating the systemic inflammatory response to adult cardiopulmonary bypass: a critical review of the evidence base. *JECT* 2014; 46: 197-211.
20. Severinghaus JW. Blood gas calculator. *J Appl Physiol* 1966; 21: 1108-1116.
21. Nunn JF, Bergman NA, Bunatyan A, et al. Temperature coefficient for PCO₂ and PO₂ of blood in vitro. *J Appl Physiol* 1965; 20: 23-26.
22. Jegger D, Tevaearai HT, Mallabiabarrena I, et al. Comparing oxygen transfer performance between three membrane oxygenators: effect of temperature changes during cardiopulmonary bypass. *Artif Organs* 2007; 31: 290-300.
23. Stammers AH, Trowbridge CC. Principles of oxygenator function: gas exchange, heat transfer, and operation. In: Gravlee GP, Davis RF, Stammers AH, Ungerleider RM (eds). *Cardiopulmonary Bypass: Principles and Practice*. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2008, pp.47-62.
24. Watts, D, Trask A, Soeken K, et al. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. *J trauma* 1998; 44: 846-854.
25. Straub A, Breuer M, Wendel HP, et al. Critical temperature ranges of hypothermia-induced platelet activation: possible implications for cooling patients in cardiac surgery. *Thromb Haemost* 2007; 97: 608-616.
26. Straub A, Krajewski S, Hohmann JD, et al. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target. *Arterioscler Thromb Vasc Biol* 2011; 31: 1607-1616.
27. Swoboda S, Grueettner J, Lang S, et al. Hypothermia inhibits expression of CD11b (MAC-1) and CD162 (PSGL-1) on monocytes during extracorporeal circulation. *In vivo* 2013; 27: 459-464.
28. Green JF, Jackman AP. Mechanism of the increased vascular capacity produced by mild perfusion hypothermia in the dog. *Circ Res* 1979; 44: 411-419.

Figure Legend

Figure 1. Scatter plot graphs of identified proteins demonstrated by log-transformed iTRAQ ratio and one-sample t-test p-values. Fold changes >1.2 or <0.833 were defined as significant up- or downregulation (indicated by two vertical lines). $P < 0.05$ was defined as statistically significant (shown by the horizontal line). Upper graphs (A) show proteins belonging to the defense system in both the hypothermic and normothermic CPB groups at midpoint (Tc/T5) of CPB. Lower graphs (B) show the above proteins in both groups at termination (Trw/T5) of CPB. iTRAQ: isobaric tags for relative and absolute quantification; CPB: cardiopulmonary bypass. a: PLG (Plasminogen, P06867); b: FGB (fibrinogen beta, F1RX37); c: FGG (uncharacterized protein, F1RX35); d: FGA (fibrinogen alpha chain, F1RX36); e: fibrinogen A-alpha-chain (N/A, Q28936); f: fibrinogen beta chain (FGB, I3L651); g: vitamin K-dependent protein C (PROC, I3LRJ4); h: SERPINC1 (uncharacterized protein, F2Z5E2).

Figure 2. Platelet degranulation activities that were evaluated by the levels of both β -TG and P-selectin in the hypothermic (HYPO) CPB group and normothermic (NORMO) CPB group. Both were measured using a sandwich ELISA kit. A: β -TG, B: P-selectin. T0, just before cardiopulmonary bypass (CPB) initiation; T5, at 5 min after CPB initiation; Tc, just before declamping (and rewarming); Trw, just before termination of CPB.

Figure 3. Blood coagulation activities that were evaluated by levels of both TAT III and protein C in the hypothermic (HYPO) group and normothermic (NORMO) CPB group. A: TAT III, B: Protein C. T0, just before cardiopulmonary bypass (CPB) initiation; Tc, just before declamping (and rewarming); Trw, just before termination of CPB.

Table 1. Arterial blood gas analysis and physiological variables at three sampling points during polymer-coating cardiopulmonary bypass

	Deep hypothermic cardiopulmonary bypass			Normothermic cardiopulmonary bypass		
	T5, 5min after ECC start, just before cooling	Tc, just before declamping, just before rewarming	Trw, just before termination of ECC	T5, 5min after ECC start	Tc, just before declamping	Trw, just before termination of ECC
pH	7.51 [7.40, 7.60]	7.42 [7.33, 7.49]	7.57 [7.53, 7.64] ^a	7.43 [7.38, 7.59]	7.32 [7.29, 7.47]	7.44 [7.35, 7.52] ^a
PCO2 (mmHg)	33.4 [26.3, 44.3]	44.7 [39.2, 57.1]	30.9 [28.9, 31.6] ^b	41.4 [32.6, 55.6]	48.4 [41.1, 54.0]	37.1 [33.0, 41.3] ^b
PO2 (mmHg)	82.0 [66.3, 286.8]	369.0[297.3, 416.8] ^c	257.0[220.0, 291.8]	228.0[173.8, 323.0]	115.5 [97.8, 177.5] ^c	207.0 [198.5, 236.5]
BE (mmol/L)	3.5 [0, 7.0]	5.0 [2.5, 6.8]	6.5 [3.3, 10.5]	7.0 [4.0, 8.3]	1.0 [-2.0, 4.0]	2.0 [-4.0, 4.0]
Na (mmol/L)	134.5 [130.3, 138.0]	134.0 [129.5, 135.5]	135.0 [132.5, 139.0]	134.0 [133.0, 136.5]	136.5 [132.3, 137.3]	137.5 [135.0, 138.5]
K (mmol/L)	4.4 [4.0, 4.9]	3.4 [3.3, 5.9]	3.6 [3.4, 3.8]	4.1 [3.8, 4.3]	4.1 [3.5, 4.5]	3.4 [3.1, 3.7]
Glucose (mg/dL)	205.5 [65.5, 268.3]	165.5 [66.0, 238.8]	142.0 [54.0, 169.3]	146.5 [85.5, 210.0]	165.5 [66.0, 238.8]	76.5 [40.5, 142.3]
Hb (g/dL)	6.2 [5.5, 6.5]	4.8 [4.4, 5.3]	7.0 [5.8, 7.9]	5.8 [5.3, 6.4]	5.8 [4.8, 7.4]	5.3 [4.3, 6.3]
Rectal temperatue (°C)	36.0 [35.7, 36.9]	23.7 [22.4, 24.3] ^d	37.0 [36.4, 37.4]	37.4 [35.6, 37.9]	35.3 [34.9, 37.4] ^d	37.4 [36.4, 38.0]
Arterial blood temperature (°C)	35.8 [35.4, 36.4]	22.7 [22.0, 23.5] ^e	39.3 [38.7, 39.6] ^f	34.7 [32.0, 36.9]	34.3 [34.1, 37.5] ^e	37.4 [37.1, 37.9] ^f
Venous blood temperature (°C)	34.6 [34.3, 36.6]	22.9 [21.9, 23.6] ^e	36.7 [36.4, 37.0]	35.6 [32.8, 36.4]	34.4 [33.9, 37.1] ^e	36.5 [36.4, 37.0]
Pump flow (L/min)	1.1 [0.7, 1.2]	0.9 [0.8, 1.2]	1.2 [0.9, 1.3]	1.1 [0.9, 1.2]	1.2 [1.0, 1.2]	1.1 [0.8, 1.3]
Gas flow (L/min)	1.0 [1.0, 1.0]	1.1 [0.8, 1.4]	1.0 [0.9, 1.4] ^h	1.0 [1.0, 1.3]	1.1 [1.0, 2.7]	1.6 [1.2, 2.6] ^h
Oxygen (FiO2)	0.65 [0.60, 1.00]	0.70 [0.65, 0.70] ⁱ	0.80 [0.70, 0.93]	0.80 [0.60, 1.00]	0.88 [0.70, 1.00] ⁱ	0.90 [0.68, 1.00]
P/F ratio ^l	125 [110, 297]	527 [425, 595] ^j	292 [285, 399]	233 [193, 538]	134 [98, 254] ^j	255 [208, 310]
Mean perfusion pressre (mmHg)	54 [39, 57]	56 [37, 62]	61 [58, 66] ^k	47 [36, 60]	61 [56, 68]	51 [42, 57] ^k

Valuables are expressed as median and quantiles [Q1, Q3]. Statistical significances between groups were assed by Mann-Whitney U test. The statistical significances (p<0.05) were as follows:

a, p = 0.010; b, p = 0.010; c, p = 0.019, d, p = 0.005; e, p = 0.004; f, p = 0.017; g, p = 0.004; h, p = 0.048; I, p = 0.045; j, p = 0.019; k, p = 0.015.

l = the ratio of arterial oxygen tension (mmHg) to fraction of inspired oxygen gas (%) (PaO₂/FiO₂).

Table 2. Significantly upregulated or downregulated plasma proteins during either normothermic or hypothermic cardiopulmonary bypass (CPB) in pigs

Uniprot KB Accession number	Protein name	Gene name	Protein function	Just before declamping (and rewarming, Tc/T5)		Just before termination of CPB (Trw/T5)	
				Deep hypothermic CPB	Normothermic CPB	Deep hypothermic CPB	Normothermic CPB
I3LGN5	Uncharacterized protein (Fragment)	Putative APOH ^a	Platelet degranulation	0.91±0.07*	0.98±0.14	1.02±0.08	0.99 ± 0.14
F1RN76	Uncharacterized protein	CD5L	Scavenger receptor activity	0.90±0.07*	0.95±0.12	0.92 ± 0.11	1.04 ± 0.19
A0A0C3SG01	Apolipoprotein A-I	APOA1	Lipid transport, platelet degranulation , scavenging of heme from plasma	0.88±0.11*	0.97±0.25	1.03 ± 0.24	1.10 ± 0.11
F1SCC7	Uncharacterized protein	Putative SERPINA3-1 ^b	Platelet degranulation, neutrophil degranulation , serine-type endopeptidase inhibitor activity	0.90±0.07*	0.97±0.22	1.05 ± 0.14	1.00 ± 0.19
F1S1A9	Uncharacterized protein	APOA2	Chylomicron assembly & remodeling	0.86±0.10*	0.96±0.21	1.08 ± 0.25	1.08 ± 0.10
I3LD86	N-acetylmuramoyl-L-alanine amidase	PGLYRP2	Peptidoglycan receptor activity	0.93±0.04*	0.96±0.38	0.95 ± 0.14	0.98 ± 0.26
A0SEH3	Complement component C8G	C8G	Terminal pathway of complement, regulation of complement cascade	0.88±0.16	0.84±0.03*	1.04 ± 0.17	0.91 ± 0.14
I3LRJ4	Vitamin K-dependent protein C	PROC	Serine-type endopeptidase activity, negative regulation of blood coagulation	1.10±0.15	0.90±0.20	1.20 ± 0.15	0.88 ± 0.01*


Mean iTRAQ ratio (Tc/T5, Tend/T5) are indicated as mean ± SD. T5: at 5minutes after CPB initiation, Tc: just before declamping (and rewarming), Trw: just before termination of CPB

*: shows significant differences ($P < 0.05$) within groups by 1-sample t-test. a: searched by Inparanoid 8, b: searched by eggNOG4.5.1


Bold face indicates "Platelet/neutrophil degranulation and blood coagulation"

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A. Defense system (complement, coagulation/fibrinolysis, and kinin-kallikrein) at midpoint of cardiopulmonary bypass (CPB)




B. Defense system (complement, coagulation/fibrinolysis, and kinin-kallikrein) at termination of cardiopulmonary bypass (CPB)



250x212mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



209x143mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

